Similarly, METTL14 was predicted to participate in HCC malignant progression by modulating the m6A-modified transcripts, such as cysteine sulfonate decarboxylase (CSAD), glutamic oxalacetic transaminase (GOT2), and SOCS2 [126]. The gene discussed is METTL14; the disease is hepatocellular carcinoma.